Abstract:Background: Disorders of mitochondrial carnitine–acylcarnitine cycle is a heterogeneous group of hereditary diseases of mitochondrial β-oxidation of fatty acids tested in NBS program in Zhejiang province, China. Large-scale studies reporting disorders of mitochondrial carnitine–acylcarnitine cycle among Chinese population in NBS are limited. The aim of this study was to explain the incidence and biochemical, clinical, and genetic characteristics of disorders of mitochondrial carnitine–acylcarnitine cycle in NBS. Methods: From January 2009 to June 2021, 4,070,375 newborns were screened by tandem mass spectrometry. Newborns with elevated C0 levels and/or C0/(C16 + C18) ratios were identified as having CPT1D, whereas those with decreased C0 levels and/or C0/(C16 + C18) ratios and/or elevated C12-C18:1 level were identified as having CPT2D or CACTD. Suspected positive patients were further subjected to genetic analysis. All confirmed patients received biochemical and nutritional treatment, as well as follow-up sessions. Results: Overall, 20 patients (12 with CPT1D, 4 with CPT2D, and 4 with CACTD) with disorders of mitochondrial carnitine–acylcarnitine cycle were diagnosed by NBS. The overall incidence of these disorders was one in 203,518 newborns. In toal, 11 patients with CPT1D exhibited increased C0 levels and C0/(C16 + C18) ratios. In all patients of CPT2D, all long chain acyl-carnitines levels were elevated except for case 14 having normal C12 levels. In all patients with CACTD, all long chain acyl-carnitines levels were elevated except for case 17 having normal C12, C18, and C18:1 levels. Most patients with CPT1D were asymptomatic. Overall, two of 4 patients with CPT2D did not present any clinical symptom, but other two patients died. In 4 cases with CACTD, the disease was onset after birth, and 75% patients died. In total, 14 distinct mutations were identified in CPT1A gene, of which 11 were novel and c.1910C > A (p.S637T), c.740C > T (p.P247L), and c.1328T > C (p.L443P) were the most common mutations. Overall, 3 novel mutations were identified in CPT2 gene, and the most frequent mutation was c.1711C > A (p.P571T). The most common variant in SLC25A20 gene was c.199-10T > G. Conclusion: Disorders of mitochondrial carnitine–acylcarnitine cycle can be detected by NBS, and the combined incidence of these disorders in newborns was rare in Zhejiang province, China. Most patients presented typical acylcarnitine profiles. Most patients with CPT1D presented normal growth and development, whereas those with CPT2D/CACTD exhibited a high mortality rate. Several novel CPT1A and CPT2 variants were identified, which expanded the variant spectrum.

Spectrum analysis of common inherited metabolic diseases in Chinese patients screened and diagnosed by tandem mass spectrometry.

[Disease Spectrum Analysis of Children with Inherited Metabolic Diseases Detected by Gas Chromatography-Mass Spectrometry of Urinary Organic Acids].

[Screening for Fatty Acid Oxidation Disorders of Newborns in Zhejiang Province:Prevalence, Outcome and Follow-Up].

[Screening for Newborn Organic Aciduria in Zhejiang Province:Prevalence, Outcome and Follow-Up].

Diseases Spectrum of Metabolism Disease of Amino Acid, Organic Acid and Fatty Acid Oxidation in Neonates

Application of Tandem Mass Spectrometry on the Diagnosis of Fatty Acid Oxidation Disorders

A Disease Spectrum Analysis of 564 Cases of Inherited Metabolic Diseases Tested by Gas Chromatography-Mass Spectrometry

[A Pilot Study of Selective Screening for High Risk Children with Inborn Error of Metabolism Using Tandem Mass Spectrometry in China].

[Diagnosis of Inborn Errors of Metabolism Using Tandem Mass Spectrometry and Gas Chromatography Mass Spectrometry].

Spectrum Analysis of Inherited Metabolic Disorders for Expanded Newborn Screening in a Central Chinese Population

Treatment and prognosis of developmental delay in children caused by inborn errors of metabolism

Clinical Onset and Prognosis of Asian Children with Organic Acidemias, As Detected by Analysis of Urinary Organic Acids Using GC/MS, Instead of Mass Screening

[Analysis of disease spectrum for abnormal 3-hydroxyisovalerylcarnitine metabolism identified through newborn screening and clinical diagnosis].

Diversity in the Incidence and Spectrum of Organic Acidemias, Fatty Acid Oxidation Disorders, and Amino Acid Disorders in Asian Countries: Selective Screening Vs. Expanded Newborn Screening

Study of application of the tandem mass spectrometry in the differential diagnosis of organic acidemias

Nationwide survey of extended newborn screening by tandem mass spectrometry in Taiwan

Screening for Inborn Errors of Metabolism in High-Risk Children: a 3-Year Pilot Study in Zhejiang Province, China

Clinical and biochemical studies on Chinese patients with methylmalonic aciduria.

Newborn Screening for Mitochondrial Carnitine-Acylcarnitine Cycle Disorders in Zhejiang Province, China

[Heterogeneous phenotypes, genotypes, treatment and prevention of 1 003 patients with methylmalonic acidemia in the mainland of China]

Prevalence of inherited metabolic disorders among newborns in Zhuzhou, a southern city in China